Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zila results

This article was originally published in The Tan Sheet

Executive Summary

Ester-C and Ester-E revenues rose 33% in the fourth quarter and 24% in fiscal year 2004 (ended July 31), the Phoenix, Ariz.-based firm reports Oct. 14. Zila ramped up production and marketing for the Ester brand by 34% in the fiscal year as the Ester-E line extension rolled out to retailers nationwide in the fourth quarter (1"The Tan Sheet" Aug. 9, 2004, In Brief). Zila's overall sales decreased 7% to $11.1 mil. in part due to discontinued saw palmetto products; the firm's fiscal 2004 sales increased 5% to $49.4 mil...
Advertisement

Related Content

Bayer Migraine Formula Seeks Market Share Before Excedrin Returns
Bayer Migraine Formula Seeks Market Share Before Excedrin Returns
Sales & Earnings In Brief
Sales & Earnings In Brief
Ester-E launch

Topics

Advertisement
UsernamePublicRestriction

Register

PS097442

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel